{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:37:26Z","timestamp":1791308246975,"version":"4.3.1"},"reference-count":30,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pfizer","award":["61034879"],"award-info":[{"award-number":["61034879"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Isavuconazole (ISA), a triazole antifungal agent, is licensed for the treatment of invasive aspergillosis and mucormycosis. Therapeutic drug monitoring (TDM) is a cornerstone of treatment efficacy for triazole antifungals due to their pharmacokinetic variability, except for ISA, for which the utility of TDM is still uncertain. We performed a retrospective study that aimed to assess the inter- and intra-individual variability of ISA trough concentrations (Cmin) and to identify the determinants involved in such variability. ISA Cmin measured in adult patients at the Grenoble Alpes University Hospital between January 2018 and August 2020 were retrospectively analyzed. In total, 304 ISA Cmin for 33 patients were analyzed. The median ISA Cmin was 2.8 [25th\u201375th percentiles: 2.0\u20133.7] mg\/L. The inter- and intra-individual variability was 41.5% and 30.7%, respectively. Multivariate analysis showed independent covariate effects of dose (\u03b2 = 0.004 \u00b1 3.56 \u00d7 10\u22124, p &lt; 0.001), Aspartate aminotransf\u00e9rase (ASAT) (\u03b2 = 0.002 \u00b1 5.41 \u00d7 10\u22124, p = 0.002), and protein levels (\u03b2 = 0.022 \u00b1 0.004, p &lt; 0.001) on ISA Cmin, whereas C reactive protein levels did not show any association. This study, conducted on a large number of ISA Cmin, shows that ISA exposure exhibits variability, explained in part by the ISA dose, and ASAT and protein levels.<\/jats:p>","DOI":"10.3390\/jcm11195756","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T22:53:19Z","timestamp":1664405599000},"page":"5756","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Variability of Isavuconazole Trough Concentrations during Longitudinal Therapeutic Drug Monitoring"],"prefix":"10.3390","volume":"11","author":[{"given":"L\u00e9a","family":"Bolcato","sequence":"first","affiliation":[{"name":"Laboratory of Pharmacology, Pharmacogenetics and Toxicology, Grenoble Alpes University Hospital, 38000 Grenoble, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Thiebaut-Bertrand","sequence":"additional","affiliation":[{"name":"Clinical Hematology Department, Grenoble Alpes University Hospital, 38000 Grenoble, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Stanke-Labesque","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology, Pharmacogenetics and Toxicology, Grenoble Alpes University Hospital, 38000 Grenoble, France"},{"name":"Faculty of Medicine, University Grenoble Alpes, Inserm, U1300, CHU Grenoble Alpes, 38000 Grenoble, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5846-3847","authenticated-orcid":false,"given":"Elodie","family":"Gautier-Veyret","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology, Pharmacogenetics and Toxicology, Grenoble Alpes University Hospital, 38000 Grenoble, France"},{"name":"Faculty of Medicine, University Grenoble Alpes, Inserm, U1300, CHU Grenoble Alpes, 38000 Grenoble, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"572","DOI":"10.5414\/CP202434","article-title":"Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH","volume":"54","author":"Desai","year":"2016","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1128\/AAC.50.1.286-293.2006","article-title":"Multiple-Dose Pharmacokinetics and Safety of the New Antifungal Triazole BAL4815 after Intravenous Infusion and Oral Administration of Its Prodrug, BAL8557, in Healthy Volunteers","volume":"50","author":"Roos","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s13318-018-0513-7","article-title":"Clinical Pharmacokinetics of Second-Generation Triazoles for the Treatment of Invasive Aspergillosis and Candidiasis","volume":"44","year":"2019","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2016","journal-title":"Haematologica"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/jac\/dky463","article-title":"Variability and exposure\u2013response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases","volume":"74","author":"Kaindl","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Wu, X., Clancy, C.J., Rivosecchi, R.M., Zhao, W., Shields, R.K., Marini, R.V., Venkataramanan, R., and Nguyen, M.H. (2018). Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients. Antimicrob. Agents Chemother., 62.","DOI":"10.1128\/AAC.01643-18"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/jac\/dkz188","article-title":"Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy","volume":"74","author":"Furfaro","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Kosmidis, C., Otu, A., Moore, C.B., Richardson, M.D., and Rautemaa-Richardson, R. (2020). Isavuconazole Therapeutic Drug Monitoring during Long-Term Treatment for Chronic Pulmonary Aspergillosis. Antimicrob. Agents Chemother., 65.","DOI":"10.1128\/AAC.01511-20"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e00585-18","DOI":"10.1128\/AAC.00585-18","article-title":"Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials","volume":"62","author":"Andes","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1128\/AAC.02819-15","article-title":"Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi","volume":"60","author":"Desai","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/cpdd.285","article-title":"Pharmacokinetic Evaluation of CYP3A4-Mediated Drug-Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol\/Norethindrone in Healthy Adults","volume":"6","author":"Townsend","year":"2016","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cca.2014.12.024","article-title":"Impact of inflammation and concomitant glucocorticoid administration on plasma concentration of triazole antifungals in immunocompromised patients","volume":"441","author":"Naito","year":"2015","journal-title":"Clin. Chim. Acta"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/jac\/dkw349","article-title":"Voriconazole metabolism is influenced by severe inflammation: A prospective study","volume":"72","author":"Veringa","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_16","first-page":"2534","article-title":"Optimization of voriconazole therapy for treatment of invasive aspergillosis: Pharmacogenomics and inflammatory status need to be evaluated","volume":"87","author":"Roustit","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Bolcato, L., Khouri, C., Veringa, A., Alffenaar, J., Yamada, T., Naito, T., Lamoureux, F., Fonrose, X., Stanke-Labesque, F., and Gautier-Veyret, E. (2021). Combined Impact of Inflammation and Pharmacogenomic Variants on Voriconazole Trough Concentrations: A Meta-Analysis of Individual Data. J. Clin. Med., 10.","DOI":"10.3390\/jcm10102089"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchromb.2012.12.028","article-title":"Simultaneous quantitation of azole antifungals, antibiotics, imatinib, and raltegravir in human plasma by two-dimensional high-performance liquid chromatography-tandem mass spectrometry","volume":"919\u2013920","author":"Jourdil","year":"2013","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/fcp.12507","article-title":"Refining the therapeutic range of posaconazole and isavuconazole for efficient therapeutic drug monitoring using a bioassay approach","volume":"34","author":"Willeman","year":"2019","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1086\/590566","article-title":"Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria","volume":"47","author":"Segal","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_21","unstructured":"The Jamovi Project (2022, August 08). jamovi (Version 1.6) [Computer Software]. Available online: https:\/\/www.jamovi.org."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Risum, M., Vestergaard, M.-B., Weinreich, U., Helleberg, M., Vissing, N., and J\u00f8rgensen, R. (2021). Therapeutic Drug Monitoring of Isavuconazole: Serum Concentration Variability and Success Rates for Reaching Target in Comparison with Voriconazole. Antibiotics, 10.","DOI":"10.3390\/antibiotics10050487"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Borman, A., Hughes, J.M., Oliver, D., Fraser, M., Sunderland, J., Noel, A.R., and Johnson, E.M. (2020). Lessons from isavuconazole therapeutic drug monitoring at a United Kingdom Reference Center. Med Mycol., 58.","DOI":"10.1093\/mmy\/myaa022"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1128\/AAC.04838-14","article-title":"Variability of Voriconazole Plasma Concentrations after Allogeneic Hematopoietic Stem Cell Transplantation: Impact of Cytochrome P450 Polymorphisms and Comedications on Initial and Subsequent Trough Levels","volume":"59","author":"Fonrose","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Gautier-Veyret, E., Bolcato, L., Roustit, M., Weiss, S., Tonini, J., Brenier-Pinchart, M.-P., Cornet, M., Thiebaut-Bertrand, A., and Stanke-Labesque, F. (2019). Treatment by Posaconazole Tablets, Compared to Posaconazole Suspension, Does Not Reduce Variability of Posaconazole Trough Concentrations. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.00484-19"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Huang, H., Xie, H., Chaphekar, N., Xu, R., Venkataramanan, R., and Wu, X. (2021). A Physiologically Based Pharmacokinetic Analysis To Predict the Pharmacokinetics of Intravenous Isavuconazole in Patients with or without Hepatic Impairment. Antimicrob. Agents Chemother., 65.","DOI":"10.1128\/AAC.02032-20"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1128\/AAC.00319-09","article-title":"Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557","volume":"53","author":"Roos","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"107627","DOI":"10.1016\/j.pharmthera.2020.107627","article-title":"Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment","volume":"215","author":"Chhun","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_29","first-page":"264","article-title":"Measurement of Free Plasma Concentrations of Beta-Lactam Antibiotics: An Applicability Study in Intensive Care Unit Patients","volume":"43","author":"Hitzenbichler","year":"2020","journal-title":"Ther. Drug Monit."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1093\/jac\/dkaa187","article-title":"Optimization of flucloxacillin dosing regimens in critically ill patients using population pharmacokinetic modelling of total and unbound concentrations","volume":"75","author":"Jager","year":"2020","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/19\/5756\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:41:25Z","timestamp":1760143285000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/19\/5756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,28]]},"references-count":30,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["jcm11195756"],"URL":"https:\/\/doi.org\/10.3390\/jcm11195756","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,28]]}}}